Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease

Jian-Jun Liu, Sujoy Ghosh, Jean-Paul Kovalik, Jianhong Ching, Hyung Won Choi, Subramaniam Tavintharan, Choon Nam Ong, Chee Fang Sum, Scott A Summers, E Shyong Tai, Su Chi Lim, Jian-Jun Liu, Sujoy Ghosh, Jean-Paul Kovalik, Jianhong Ching, Hyung Won Choi, Subramaniam Tavintharan, Choon Nam Ong, Chee Fang Sum, Scott A Summers, E Shyong Tai, Su Chi Lim

Abstract

Introduction: Pathophysiology of diabetic kidney disease (DKD) is incompletely understood. We aim to elucidate metabolic abnormalities associated with DKD in type 2 diabetes mellitus (T2DM) by targeted plasma metabolomics.

Methods: A total of 126 T2DM participants with early DKD (urinary albumin-to-creatinine ratio [ACR] 30-299 mg/g and eGFR ≥ 60 ml/min/1.73 m2), 154 overt DKD (ACR ≥ 300 mg/g or eGFR < 60 ml/min/1.73 m2), and 129 non-DKD T2DM controls (ACR < 30 mg/g and eGFR ≥ 60 ml/min/1.73 m2) were included in discovery study. Findings were subsequently validated in 149 T2DM with macroalbuminuria (ACR ≥ 300 mg/g) and 149 matched non-DKD T2DM controls. Plasma amino acid, acylcarnitine, Krebs cycle organic acid, and sphingolipids/ceramide levels were quantified by liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry.

Results: Of 123 metabolites included in the data analysis, 24 differed significantly between DKD and controls in the same direction in both discovery and validation subpopulations. A number of short acylcarnitines including their dicarboxylic derivatives (C2-C6) were elevated in DKD, suggesting abnormalities in fatty acids and amino acids metabolic pathways. Five phosphatidylcholines were lower whereas 4 metabolites in the sphingomyelin-ceramide subfamily were higher in DKD. Principal component regression revealed that long-chain ceramides were independently associated with ACR but not eGFR. Conversely, essential amino acids catabolism and short dicarboxylacylcarnitine accumulation were associated with eGFR but not ACR.

Discussion: DKD is associated with altered fuel substrate use and remodeling of sphingolipid metabolism in T2DM with DKD. Associations of albuminuria and impaired filtration function with distinct metabolomic signatures suggest different pathophysiology underlying these 2 manifestations of DKD.

Keywords: diabetic kidney disease; energetic fuel substrate; metabolomics; pathophysiology; type 2 diabetes mellitus.

Figures

Figure 1
Figure 1
Plasma metabolites that differed significantly between diabetic kidney disease (DKD) patients and non-DKD controls in the same direction in both discovery and validation subpopulations (highlighted in red) and the potential metabolic pathways associcated with DKD. AC, acylcarnitine; CPT-1, carnitine palmitoyltransferase I; ER, endoplasmic reticulum; FFA, free fatty acid; LCDA, long-chain dicarboxylic acid; NF-κB, nuclear factor−κB; PDC, pyruvate dehydrogenase complex; SCDA, short-chain diacids; SM, sphingomyelin; TCA, tricarboxylic acid cycle.

References

    1. Parving H.H., Lewis J.B., Ravid M. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int. 2006;69:2057–2063.
    1. Tuttle K.R., Bakris G.L., Bilous R.W. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864–2883.
    1. Gregg E.W., Li Y., Wang J. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514–1523.
    1. Stanton R.C. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014;63:S3–S21.
    1. Shah S.H., Kraus W.E., Newgard C.B. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: Form and function. Circulation. 2012;126:1110–1120.
    1. Yu B., Zheng Y., Nettleton J.A. Serum metabolomic profiling and incident CKD among African Americans. Clin J Am Soc Nephrol. 2014;9:1410–1417.
    1. Macisaac R.J., Ekinci E.I., Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63:S39–S62.
    1. Rhee E.P. Metabolomics and renal disease. Curr Opin Nephrol Hypertens. 2015;24:371–379.
    1. Sharma K., Karl B., Mathew A.V. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24:1901–1912.
    1. Zhang Y., Zhang S., Wang G. Metabolomic biomarkers in diabetic kidney diseases: A systematic review. J Diabetes Complications. 2015;29:1345–1351.
    1. Niewczas M.A., Sirich T.L., Mathew A.V. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: Metabolomic study. Kidney Int. 2014;85:1214–1224.
    1. Ng D.P., Salim A., Liu Y. A metabolomic study of low estimated GFR in non-proteinuric type 2 diabetes mellitus. Diabetologia. 2012;55:499–508.
    1. Goek O.N., Doring A., Gieger C. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis. 2012;60:197–206.
    1. Makinen V.P., Tynkkynen T., Soininen P. Sphingomyelin is associated with kidney disease in type 1 diabetes (the FinnDiane Study) Metabolomics. 2012;8:369–375.
    1. Ekinci E.I., Jerums G., Skene A. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36:3620–3626.
    1. Shimizu M., Furuichi K., Toyama T. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013;36:3655–3662.
    1. Wanner C., Inzucchi S.E., Lachin J.M. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
    1. Muoio D.M., Noland R.C., Kovalik J.P. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab. 2012;15:764–777.
    1. Newgard C.B., An J., Bain J.R. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311–326.
    1. Sinha R.A., Farah B.L., Singh B.K. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology. 2014;59:1366–1380.
    1. Loh P.T., Toh M.P., Molina J.A. Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster. Nephrology (Carlton) 2015;20:216–223.
    1. Kraus W.E., Muoio D.M., Stevens R. Metabolomic quantitative trait loci (mQTL) mapping implicates the ubiquitin proteasome system in cardiovascular disease pathogenesis. PLoS Genet. 2015;11:e1005553.
    1. Adams S.H., Hoppel C.L., Lok K.H. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009;139:1073–1081.
    1. Koves T.R., Ussher J.R., Noland R.C. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7:45–56.
    1. Newgard C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15:606–614.
    1. Schooneman M.G., Vaz F.M., Houten S.M. Acylcarnitines: Reflecting or inflicting insulin resistance? Diabetes. 2013;62:1–8.
    1. Wanders R.J., Komen J., Kemp S. Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS J. 2011;278:182–194.
    1. Libert R., Van Hoof F., Laus G. Identification of ethylsuccinylcarnitine present in some human urines. Clin Chim Acta. 2005;355:145–151.
    1. van der Kloet F.M., Tempels F.W., Ismail N. Discovery of early-stage biomarkers for diabetic kidney disease using MS-based metabolomics (FinnDiane study) Metabolomics. 2012;8:109–119.
    1. Weber J.M., Haman F. Oxidative fuel selection: Adjusting mix and flux to stay alive. Int Congress Series. 2004;1275:22–31.
    1. Overmyer K.A., Evans C.R., Qi N.R. Maximal oxidative capacity during exercise is associated with skeletal muscle fuel selection and dynamic changes in mitochondrial protein acetylation. Cell Metab. 2015;21:468–478.
    1. Kelley D.E., Mandarino L.J. Fuel selection in human skeletal muscle in insulin resistance: A reexamination. Diabetes. 2000;49:677–683.
    1. McCoin C.S., Knotts T.A., Adams S.H. Acylcarnitines–old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol. 2015;11:617–625.
    1. Sim K.G., Hammond J., Wilcken B. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin Chim Acta. 2002;323:37–58.
    1. Dugan L.L., You Y.H., Ali S.S. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123:4888–4899.
    1. Sharma K. Mitochondrial hormesis and diabetic complications. Diabetes. 2015;64:663–672.
    1. Morino K., Petersen K.F., Shulman G.I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55(suppl 2):S9–S15.
    1. Le Page L.M., Rider O.J., Lewis A.J. Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: A combined 13C hyperpolarized magnetic resonance and echocardiography study. Diabetes. 2015;64:2735–2743.
    1. Gadian D., Radda G., Ross B. Examination of a myopathy by phosphorus nuclear magnetic resonance. Lancet. 1981;2:774–775.
    1. Galadari S., Rahman A., Pallichankandy S. Role of ceramide in diabetes mellitus: Evidence and mechanisms. Lipids Health Dis. 2013;12:98.
    1. Marggraf W.D., Zertani R., Anderer F.A. The role of endogenous phosphatidylcholine and ceramide in the biosynthesis of sphingomyelin in mouse fibroblasts. Biochim Biophys Acta. 1982;710:314–323.
    1. Gansevoort R.T., Matsushita K., van der Velde M. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104.
    1. Ellis J.W., Chen M.H., Foster M.C. Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet. 2012;21:3293–3298.
    1. Boini K.M., Zhang C., Xia M. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther. 2010;334:839–846.
    1. Zhu C., Liang Q.L., Hu P. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta. 2011;85:1711–1720.
    1. Shiffman D., Pare G., Oberbauer R. A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND. PLoS One. 2014;9:e106631.
    1. de Boer I.H., Steffes M.W. Glomerular filtration rate and albuminuria: Twin manifestations of nephropathy in diabetes. J Am Soc Nephrol. 2007;18:1036–1037.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit